NCT04553419招募中3 期
Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF (ASAP-CF) Clinical Research Protocol
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 86
- 试验地点
- 2
- 主要终点
- The relative change in LCI2.5 between day 0 and day 14 (relative change = [LCI2.5 at day 14-LCI2.5 at day 0]/LCI2.5 at day 0).
研究概览
简要总结
This is a randomized, double-blinded study that aims to assess the effect of an oral antibiotic called Cephalexin (150 mg/kg/day) compared to placebo in clinically stable children with cystic fibrosis who have grown a bacteria called MSSA (methicillin-susceptible Staphylococcus aureus) over the course of 2 weeks.
A sensitive technique called MBW (multiple breath washout) will be used to look at how well the participants lungs are functioning during the study and to see if the antibiotic improves function. The primary outcome of the study will be the relative change in the MBW measurement (LCI2.5) between day 0 and day 14 of study treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
double-blinded
入排标准
- 年龄范围
- 3 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:
- •A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT)
- •A documented genotype with two disease-causing mutations in the CFTR gene
- •Age 3 years and over, up to 17th birthday.
- •Weight ≥ 10.0kg
- •No increase in lower respiratory tract symptoms from baseline for 28 days.
- •At least one episode of MSSA growth on airway culture in the past 24 months OR the past 10 airway cultures, which ever is greater.
- •Successful MBW test occasion at the Screening Visit, per the assessment of the Site MBW Operator.
- •Informed consent by participant or parent/legal guardian with written assent where age-appropriate.
- •Randomization inclusion at each visit(applied after every Study Visit in the Phase 1)
- •Growth of isolated MSSA on bacterial airway culture from this Study Visit, including cultures collected up to 21 days before this study visit.
- •Acceptable MBW test at this Study Visit, per the assessment of the Site MBW Operator.
- •Participant willing to be randomised.
排除标准
- •Change of any respiratory medications within 28 days of enrollment (i.e. recent increase in pancreatic enzyme dosing, or similar, is not an exclusion).
- •Chronic infection with any of the following: Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia or Achromobacter spp, MRSA or any non-tuberculous mycobacteria, where chronic infection is defined as ≥50% positive airway cultures over the previous 12 months or the past 4 airway cultures, which ever is greater (latest culture cannot be positive for Pseudomonas auruginosa).
- •Chronic daily antibiotic use (oral, inhaled or intravenous; including azithromycin or cycling month inhaled antibiotics).
- •Systemic corticosteroid use for any indication within 28 days.
- •Allergic bronchopulmonary aspergillosis (ABPA) requiring corticosteroid therapy within 12 months.
- •Known allergy to cephalexin or other cephalosporins.
- •Previous organ transplantation.
- •Clinical findings that, in the opinion of the Site Investigator, would compromise the safety of the participant or the quality of the study data.
- •Known pregnancy or planning to become pregnant during the study.
- •Randomisation exclusion(applied after every Study Visit in the Phase 1)
- •Increase in respiratory (upper or lower) symptoms from baseline in the previous 28 days.
- •Diagnosis of a pulmonary exacerbation by the treating physician at the Study Visit.
- •Change of any respiratory medications within 28 days.
- •New diagnosis of allergic bronchopulmonary aspergillosis (ABPA) since previous encounter.
- •New use of chronic daily antibiotics since previous encounter.
- •Clinical findings that, in the opinion of the Site Investigator, would compromise the safety of the participant or the quality of the study data.
研究组 & 干预措施
Cephalexin
Experimental
Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
干预措施: Cephalexin (Drug)
Placebo
Placebo Comparator
The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
The relative change in LCI2.5 between day 0 and day 14 (relative change = [LCI2.5 at day 14-LCI2.5 at day 0]/LCI2.5 at day 0).
时间窗: 14 days from randomization
Lung clearance index (LCI) as measured using the multiple breath nitrogen washout (MBW) technique with the Exhlayzer D (Eco Medics, Durnten SUI) device.
次要结局
- Relative change in LCI5 between day 0 and day 14.(14 days from randomization)
- MSSA airway culture positivity at day 14(14 days from randomization)
- Time to next pulmonary exacerbation(up to 12 months)
- Number of new CF respiratory pathogens (P. aeruginosa etc) from clinical respiratory samples(up to 12 months)
- Relative change in percent predicted FEV1 between day 0 and day 14(14 days from randomization)
- Absolute change in the CFQ-R(R) between day 0 and day 14.(up to 12 months)
- Time until next growth of MSSA on clinical microbiology samples(up to 12 months)
- Absolute change in FEV1 (mL) between day 0 and day 14(14 days from randomization)
研究者
Jonathan Rayment
Clinical Associate Professor
University of British Columbia
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.Rectal CancerNCT03436719State Scientific Centre of Coloproctology, Russian Federation280
已完成
4 期
TOX NEG Trial: Clostridium Difficile Diagnosis and TreatmentClostridium Difficile InfectionDiarrheaNCT03388268Washington University School of Medicine15
招募中
2 期
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MVGram Negative PneumoniaGram-Negative Bacterial InfectionsBacteremia Caused by Gram-Negative BacteriaNCT06135350Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation234
已完成
2 期
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary DiseaseNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)NCT05496374Spero Therapeutics25
已完成
3 期
A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.SinusitisNCT00236522Johnson & Johnson Pharmaceutical Research & Development, L.L.C.784